|
US7563874B2
(en)
*
|
1998-08-31 |
2009-07-21 |
The Regents Of The University Of California |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
IL147765A0
(en)
*
|
1999-07-29 |
2002-08-14 |
Medarex Inc |
HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
|
|
DK1276855T3
(da)
*
|
2000-04-17 |
2012-11-26 |
Dyax Corp |
Fremgangsmåde til konstruktion af visningsbiblioteker over genetiske pakker for medlemmer af en diversificeret peptidfamilie
|
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
|
PT1282443E
(pt)
|
2000-05-19 |
2009-12-04 |
Genentech Inc |
Análise de detecção génica para melhorar a probabilidade de uma resposta eficaz a uma terapia do cancro com um antagonista de erbb
|
|
DK1360288T3
(da)
|
2000-12-18 |
2011-06-14 |
Dyax Corp |
Fokuserede biblioteker af genetiske pakker
|
|
ITRM20010408A1
(it)
*
|
2001-07-10 |
2003-01-10 |
Univ Napoli Federico Ii |
Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
|
|
JPWO2003009870A1
(ja)
*
|
2001-07-25 |
2004-11-11 |
三菱ウェルファーマ株式会社 |
乳癌治療薬
|
|
EP1539235A2
(en)
|
2002-07-01 |
2005-06-15 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to reg iv
|
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
|
US6987270B2
(en)
|
2003-05-07 |
2006-01-17 |
General Electric Company |
Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
|
|
EP1663171B9
(en)
|
2003-08-26 |
2009-08-19 |
SmithKline Beecham Corporation |
Heterofunctional copolymers of glycerol and polyethylene glycol, their conjugates and compositions
|
|
US20080267865A1
(en)
*
|
2003-11-28 |
2008-10-30 |
Biotech Igg Ab |
Targeting of Erb Antigens
|
|
UA86063C2
(ru)
|
2004-05-03 |
2009-03-25 |
Хермес Біосайенсез, Інк. |
Липосомы для снабжения лекарств
|
|
WO2006042270A1
(en)
|
2004-10-08 |
2006-04-20 |
Alza Corporation |
Method of inserion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
|
|
UA94899C2
(ru)
|
2005-01-21 |
2011-06-25 |
Дженентек, Инк. |
Фиксированное дозирование антител к her
|
|
AU2006332045A1
(en)
*
|
2005-01-27 |
2007-08-16 |
The Regents Of The University Of California |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
|
GB0503546D0
(en)
*
|
2005-02-21 |
2005-03-30 |
Hellenic Pasteur Inst |
Antibody
|
|
DK1850874T3
(da)
|
2005-02-23 |
2013-11-11 |
Genentech Inc |
Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
|
|
WO2008019290A2
(en)
*
|
2006-08-04 |
2008-02-14 |
Astrazeneca Ab |
Human antibodies to erbb 2
|
|
CA2672393C
(en)
*
|
2006-12-12 |
2014-11-18 |
Morphosys Ag |
Internalization
|
|
BRPI0808418A2
(pt)
|
2007-03-02 |
2014-07-22 |
Genentech, Inc |
Predição de resposta a um inibidor de her
|
|
WO2009008916A2
(en)
|
2007-03-22 |
2009-01-15 |
The Regents Of The University Of Californina |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
|
WO2008141274A1
(en)
|
2007-05-11 |
2008-11-20 |
Centocor, Inc. |
Anti-alpha v immunoliposome composition, methods and uses
|
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
ES2583377T3
(es)
|
2007-06-08 |
2016-09-20 |
Genentech, Inc. |
Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
|
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
US12529164B2
(en)
|
2007-09-14 |
2026-01-20 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
JP5933894B2
(ja)
|
2007-09-14 |
2016-06-15 |
アディマブ， エルエルシー |
合理的に設計された、合成抗体ライブラリおよびその使用
|
|
WO2009114815A1
(en)
|
2008-03-13 |
2009-09-17 |
Dyax Corp |
Libraries of genetic packages comprising novel hc cdr3 designs
|
|
WO2009132287A2
(en)
|
2008-04-24 |
2009-10-29 |
Dyax Corp. |
Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
EP2313434A4
(en)
|
2008-07-31 |
2013-03-27 |
Univ California |
ANTIBODIES FOR NEUTRALIZING BOTULINE NEUROTOXINES
|
|
CA2779436A1
(en)
|
2008-10-31 |
2010-05-06 |
Biogen Idec Ma Inc. |
Light targeting molecules and uses thereof
|
|
NZ594665A
(en)
|
2009-03-20 |
2013-08-30 |
Genentech Inc |
Bispecific anti-her antibodies
|
|
SG176073A1
(en)
|
2009-05-29 |
2011-12-29 |
Hoffmann La Roche |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
|
MX2012008958A
(es)
|
2010-02-18 |
2012-08-23 |
Genentech Inc |
Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
|
|
TW201141519A
(en)
*
|
2010-03-04 |
2011-12-01 |
Symphogen As |
Anti-HER2 antibodies and compositions
|
|
US8609095B2
(en)
|
2010-03-04 |
2013-12-17 |
Symphogen A/S |
Anti-HER2 antibodies and compositions
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
US9714294B2
(en)
|
2010-05-27 |
2017-07-25 |
Genmab A/S |
Monoclonal antibodies against HER2 epitope
|
|
CA3051311A1
(en)
|
2010-05-27 |
2011-12-01 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
KR102810907B1
(ko)
|
2010-07-16 |
2025-05-21 |
아디맵 엘엘씨 |
항체 라이브러리
|
|
WO2012047427A2
(en)
|
2010-08-31 |
2012-04-12 |
The Regents Of The University Of California |
Antibodies for botulinum neurotoxins
|
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
|
CN103327983A
(zh)
|
2010-12-06 |
2013-09-25 |
梅里麦克制药股份有限公司 |
在使用包含蒽环类化疗剂的erbb2靶向免疫脂质体的治疗中防止心肌毒性的剂量和给药
|
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
|
AU2012217685B2
(en)
|
2011-02-15 |
2017-05-18 |
Merrimack Pharmaceuticals, Inc. |
Compositions and methods for delivering nucleic acid to a cell
|
|
AU2012245116A1
(en)
|
2011-04-20 |
2013-11-07 |
Genmab A/S |
Bispecific antibodies against HER2 and CD3
|
|
EP2699260B1
(en)
|
2011-04-20 |
2024-11-20 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
JP6177231B2
(ja)
|
2011-04-20 |
2017-08-09 |
ゲンマブ エー／エス |
Ｈｅｒ２に対する二重特異性抗体
|
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
|
WO2013043864A1
(en)
*
|
2011-09-23 |
2013-03-28 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to endothelial targeting
|
|
US9327023B2
(en)
|
2011-10-25 |
2016-05-03 |
The Regents Of The University Of Michigan |
HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
|
|
RU2019103083A
(ru)
|
2011-11-30 |
2019-03-22 |
Дженентек, Инк. |
МУТАЦИИ ErbB3 ПРИ РАКЕ
|
|
EP2788500A1
(en)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
|
WO2013148315A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
|
US9717724B2
(en)
|
2012-06-13 |
2017-08-01 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies
|
|
AU2013202947B2
(en)
|
2012-06-13 |
2016-06-02 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
|
|
WO2013192294A1
(en)
*
|
2012-06-20 |
2013-12-27 |
Boston 3T Biotechnologies, Inc. |
Cellular therapies for treating and preventing cancers and other immune system disorders
|
|
JP6998646B2
(ja)
|
2012-11-30 |
2022-02-04 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
|
|
WO2014089127A1
(en)
|
2012-12-03 |
2014-06-12 |
Merrimack Pharmaceuticals, Inc. |
Combination therapy for treating her2-positive cancers
|
|
WO2015066543A1
(en)
*
|
2013-11-01 |
2015-05-07 |
Board Of Regents, The University Of Texas System |
Targeting her2 and her3 with bispecific antibodies in cancerous cells
|
|
ES2819863T3
(es)
|
2014-04-11 |
2021-04-19 |
Medimmune Llc |
Anticuerpos contra HER2 biespecíficos
|
|
TWI695011B
(zh)
*
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗ｈｅｒ２表位之單株抗體及其使用之方法
|
|
US20160045596A1
(en)
|
2014-08-05 |
2016-02-18 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
|
|
EP3957317A1
(en)
|
2015-02-06 |
2022-02-23 |
The Regents of The University of California |
Methods and compositions for improved cognition
|
|
CN107614762B
(zh)
*
|
2015-02-24 |
2022-08-05 |
台湾地区“中央研究院” |
一种由噬菌体表达的单链变异片段抗体库
|
|
US11318131B2
(en)
|
2015-05-18 |
2022-05-03 |
Ipsen Biopharm Ltd. |
Nanoliposomal irinotecan for use in treating small cell lung cancer
|
|
PL3337467T3
(pl)
|
2015-08-20 |
2021-06-14 |
Ipsen Biopharm Ltd. |
Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu
|
|
IL257149B2
(en)
|
2015-08-21 |
2024-11-01 |
Ipsen Biopharm Ltd |
Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
|
|
MX382522B
(es)
|
2015-10-16 |
2025-03-13 |
Ipsen Biopharm Ltd |
Composiciones farmaceuticas estabilizantes de camptotecina.
|
|
US20180271998A1
(en)
|
2015-12-04 |
2018-09-27 |
Merrimack Pharmaceuticals, Inc. |
Disulfide-stabilized fabs
|
|
EA201891178A1
(ru)
|
2015-12-14 |
2019-01-31 |
Макродженикс, Инк. |
Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
|
|
US20190151346A1
(en)
|
2016-05-10 |
2019-05-23 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
|
EP3535026A1
(en)
|
2016-11-02 |
2019-09-11 |
Ipsen Biopharm Limited |
Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
|
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
|
SG11201907753TA
(en)
|
2017-02-24 |
2019-09-27 |
Macrogenics Inc |
Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
|
|
WO2019118266A1
(en)
|
2017-12-12 |
2019-06-20 |
Macrogenics Inc. |
Bispecific cd 16-binding molecules and their use in the treatment of disease
|
|
WO2019160904A1
(en)
|
2018-02-15 |
2019-08-22 |
Macrogenics, Inc. |
Variant cd3-binding domains and their use in combination therapies for the treatment of disease
|
|
WO2020163306A1
(en)
|
2019-02-04 |
2020-08-13 |
The Regents Of The University Of California |
Exercise-induced circulatory factors for amelioration of cognitive, neurological, and regenerative dysfunction during aging
|
|
US20230181691A1
(en)
|
2020-02-12 |
2023-06-15 |
The Regents Of The University Of California |
Platelet factors and cognitive improvement
|
|
CA3170330A1
(en)
|
2020-02-21 |
2021-08-26 |
Macrogenics, Inc. |
Cd137 binding molecules and uses thereof
|
|
CN116635064A
(zh)
|
2020-12-18 |
2023-08-22 |
世纪治疗股份有限公司 |
具有适应性受体特异性的嵌合抗原受体系统
|
|
US12428457B2
(en)
|
2021-01-29 |
2025-09-30 |
University Of South Florida |
Cold-shock protein scaffold for engineering non-antibody binding proteins
|
|
TW202434279A
(zh)
|
2022-10-28 |
2024-09-01 |
美商聯合生物技術公司 |
用於改善認知之方法
|
|
EP4414386A1
(en)
|
2023-02-09 |
2024-08-14 |
Mariangela Figini |
Method of chemical synthesis of single-chain antibody fragments and products thereby obtained
|
|
NL2038054B1
(en)
|
2024-06-25 |
2026-01-15 |
Academisch Ziekenhuis Leiden |
A method for preparing liposomes
|